Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Budesonide
Drug ID BADD_D00306
Description Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994.[L10598]
Indications and Usage Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease.[L10601,L10604] Various inhaled budesonide products are indicated for prophylactic therapy in asthma[L10607,L10613,L10619] and reducing exacerbations of COPD.[L10619] A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies.[L10616] Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis[L10622] and a rectal foam is used for mild to moderate distal ulcerative colitis.[L10625] In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression.[L39479]
Marketing Status approved
ATC Code A07EA06; D07AC09; R01AD05; R03BA02
DrugBank ID DB01222
KEGG ID D00246
MeSH ID D019819
PubChem ID 5281004
TTD Drug ID D0Y7IU
NDC Product Code 46439-8719; 49076-6111; 53104-7617; 16714-019; 0115-1689; 46122-389; 50090-2239; 51407-366; 68788-7290; 0536-1112; 70771-1075; 0904-7166; 0591-2510; 38779-3097; 64918-0204; 0093-6816; 0186-1989; 49035-703; 63629-8294; 68012-309; 0487-9601; 55154-4849; 0378-4500; 76282-641; 49452-1291; 52128-133; 65089-0024; 16714-829; 0093-6815; 45802-627; 47335-633; 68682-658; 69097-321; 69842-001; 0781-7516; 15308-0100; 52221-117; 16714-020; 0115-1687; 0186-1988; 60687-596; 68682-309; 68788-7314; 76282-640; 81749-004; 46439-8737; 60870-0466; 63190-0060; 63592-0187; 64918-0205; 66412-0393; 68743-309; 73377-076; 11822-1700; 0186-1990; 51862-580; 55566-1002; 55566-1020; 68788-8429; 0574-9855; 51552-1365; 21130-710; 0093-6817; 47335-632; 0186-0916; 0186-0917; 60505-6129; 63629-9093; 65162-778; 68382-720; 69097-318; 69097-319; 0781-7517; 49452-1292; 68981-017; 47335-631; 0363-0048; 64980-255; 65649-651; 49927-0004; 0487-9701; 76282-642; 0781-7515; 10695-124; 50546-580; 51508-004; 53183-6310; 65089-0005; 71052-270; 16714-018; 50580-646; 51407-128
UNII Q3OKS62Q6X
Synonyms Budesonide | Budesonide, (S)-Isomer | Pulmicort | Rhinocort | Budesonide, (R)-Isomer | Horacort
Chemical Information
Molecular Formula C25H34O6
CAS Registry Number 51333-22-3
SMILES CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Large intestinal stenosis07.13.03.004--
Gastrointestinal wall thickening07.01.06.032--Not Available
End stage renal disease20.01.03.0190.000186%Not Available
Behaviour disorder19.01.01.0050.000326%Not Available
Cortisol decreased13.10.09.013--Not Available
Cross sensitivity reaction10.01.01.0360.000093%Not Available
Drug effect less than expected08.06.01.036--Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.000577%Not Available
Eosinophilic granulomatosis with polyangiitis22.01.01.025; 24.12.04.010; 10.02.02.031; 01.02.04.022--Not Available
Fear of injection19.06.03.016--Not Available
Gait inability17.02.05.069; 08.01.02.011--Not Available
Gastrointestinal scarring07.13.01.015--Not Available
Growth failure15.03.05.015; 14.03.02.030; 05.03.02.0060.002884%Not Available
Idiopathic intracranial hypertension17.07.02.011--Not Available
Illness08.01.03.091--Not Available
Intermenstrual bleeding21.01.01.0150.000363%Not Available
Loss of therapeutic response08.06.01.041--Not Available
NSAID exacerbated respiratory disease22.03.01.027; 10.01.01.0390.000093%Not Available
Oesophageal carcinoma recurrent16.13.06.005; 07.21.06.0050.000140%Not Available
Pharyngeal swelling22.04.05.028--Not Available
Precursor B-lymphoblastic lymphoma16.28.10.001; 01.15.10.0010.000093%Not Available
Reaction to excipient10.01.01.0420.000251%Not Available
Spinal stenosis15.10.04.014; 17.10.01.0310.000093%Not Available
Therapeutic product effect decreased08.06.01.0500.000567%Not Available
Therapeutic product effect delayed08.06.01.051--Not Available
Therapeutic product effect incomplete08.06.01.0520.000660%Not Available
Therapeutic product effective for unapproved indication12.09.02.004; 08.06.01.0560.000205%Not Available
Therapeutic product ineffective08.06.01.057--Not Available
Therapeutic response shortened08.06.01.062--Not Available
Therapy non-responder08.06.01.0630.000642%Not Available
The 18th Page    First    Pre   18 19    Next   Last    Total 19 Pages